Form 6-K CHINA LIFE INSURANCE CO For: Dec 29
- Wall Street ends down, but indexes briefly cut losses after Fed minutes
- Bed Bath & Beyond (BBBY) Falls as Cohen Files to Sell His ~9.5M Shares
- Cisco Systems Reports Q4 Beat, Provides Outlook, Shares Up 3%
- Target (TGT) Falls on Big EPS Miss, Analyst Says Results are 'Disappointing'
- This Rule with a Perfect Track Record Says the Market Hasn't Bottomed - BofA
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Commission File Number 001-31914
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 29, 2021
China Life Insurance Company Limited
(Translation of registrants name into English)
16 Financial Street
Beijing 100033, China
Tel: (86-10) 6363-3333
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ☐
China Life Insurance Company Limited issued an announcement on December 29, 2021, a copy of which is attached as Exhibit 99.1 hereto.
Commission File Number 001-31914
|99.1||Announcement, dated December 29, 2021|
Commission File Number 001-31914
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|By:||/s/ Su Hengxuan|
|December 29, 2021||
President and Executive Director
CHINA LIFE INSURANCE COMPANY LIMITED
(A joint stock limited company incorporated in the Peoples Republic of China with limited liability)
(Stock Code: 2628)
CONNECTED TRANSACTIONS IN RELATION TO THE FORMATION OF PARTNERSHIPS
Reference is made to two announcements of China Life Insurance Company Limited (the Company) dated 16 December 2021 (the Announcements) in relation to (i) connected transactions regarding the investment by the Company in Xinyuan Partnership and Xindian Partnership through equity investment plans, and (ii) a connected transaction regarding the investment by the Company in China Life Chengda (Wuxi) Equity Investment Center (Limited Partnership)(Wuxi Partnership). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.
The Company wishes to provide further information of Xinyuan Partnership, Xindian Partnership and Wuxi Partnership as follows:
XINYUAN PARTNERSHIP AND XINDIAN PARTNERSHIP
Xinyuan Partnership and Xindian Partnership will primarily invest in green and low-carbon investment targets (such as wind power, photovoltaic power, energy storage and other clean energy projects), with particular focus on the projects satisfying the following requirements:
The estimated internal rate of return of the investment project shall not be lower than 6%, subject to adjustment based on the macroeconomic situation, capital market conditions, strategic development needs and other actual circumstances;
The investment project shall comply with national industrial policies, such as the Guiding Opinions of the State Council on Accelerating the Establishment of a Sound Green, Low-Carbon and Cyclic Economic System (Guo Fa  No. 4), the legal procedures for the establishment, development, construction and operation of the investment project have been fulfilled, and the project company has no adverse credit records in the last two years; and
In principle, the shareholding ratio of Xinyuan Partnership / Xindian Partnership in the project company shall not be less than 34%, and the capital ratio of the investment project shall not be less than 20% of the total investment amount of the project. Further, the investment amount of Xinyuan Partnership / Xindian Partnership in any single project shall not exceed 50% of the total capital contribution by all partners.
Wuxi Partnership will primarily make direct or indirect investment in private equity projects in the medical health and technological innovation sectors, with particular focus on the projects satisfying the following requirements:
With respect to the investment in the medical health sector, Wuxi Partnership will focus on four core areas, including life science, medical technology, medical services and distribution, as well as digital medical care, with a view to creating an inclusive healthcare industry ecosystem, and target on high-quality companies with strong independent research and development capability, leading platform technology and prominent domestic substitution advantages;
With respect to the investment in the technological innovation sector, Wuxi Partnership will focus on three areas, including new infrastructures, core technology platforms and industrial upgrade applications in the new economic era, and target on premium technology companies with leading technology advantages, clear business model and high financial and investment value. Specifically, new infrastructures mainly refer to the infrastructure assets that drive the digital and intelligent transformation of the economy; core technology platforms mainly refer to those platforms using technologies including cloud computing, big data, artificial intelligence, semiconductors and intelligent terminals; and industrial upgrade applications mainly refer to new applications and new models for the digital and intelligent transformation of traditional industries such as medical care;
The estimated internal rate of return of the investment project shall not be lower than 8%, subject to adjustment based on the macroeconomic situation, capital market conditions, strategic development needs and other actual circumstances; and
The investment amount of Wuxi Partnership in any single project shall not exceed 20% of the total capital contribution by all partners. Further, without the consent of the investment advisory committee, the amount of investment made by Wuxi Partnership in any private equity funds managed by third party managers shall not exceed 20% of the total capital contribution by all partners.
|By Order of the Board|
|China Life Insurance Company Limited|
|Heng Victor Ja Wei|
Hong Kong, 29 December 2021
As at the date of this announcement, the Board of the Company comprises:
|Executive Directors:||Wang Bin, Su Hengxuan, Li Mingguang, Huang Xiumei|
|Non-executive Directors:||Yuan Changqing, Wang Junhui|
|Independent Non-executive Directors:||Tang Xin, Leung Oi-Sie Elsie, Lam Chi Kuen, Zhai Haitao|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba (BABA), Others on Watch as Three Chinese Companies to Delist ADSs
- H1-2022 Interim Report – 61% growth in revenue compared to last year. Significant investments into the fleet
- China Life Insurance Company Limited
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!